Products

Products

View as  
 
Apalutamide

Apalutamide

Apalutamide (CAS 956104-40-8) is an orally administered, non-steroidal androgen receptor (AR) inhibitor. The molecule features a thiohydantoin core with a 4-cyano-3-(trifluoromethyl)phenyl group and a cyclobutyl substituent.
Niraparib tosylate

Niraparib tosylate

Niraparib Tosylate (CAS 1613220-15-7) is an orally bioavailable, hydrated tosylate salt form of niraparib, an inhibitor of poly (ADP-ribose) polymerase (PARP) types 1 and 2 (PARP-1 and -2). The molecule binds to and inhibits PARP-1 and -2 activity, thereby inhibiting PARP-mediated DNA repair, enhancing the accumulation of DNA strand breaks, promoting genomic instability, and resulting in apoptosis .
Ifosfamide

Ifosfamide

Ifosfamide (CAS 3778-73-2) is a synthetic oxazaphosphorine alkylating agent structurally isomeric with cyclophosphamide. The molecule features a six-membered 1,3,2-oxazaphosphorinane 2-oxide ring bearing two 2-chloroethyl side chains—one attached to the ring nitrogen and the other to the exocyclic amino group.
Lapatinib Ditosylate Monohydrate

Lapatinib Ditosylate Monohydrate

Lapatinib Ditosylate Monohydrate (CAS 388082-78-8) is a synthetic, orally active quinazoline-based small molecule that functions as a reversible dual tyrosine kinase inhibitor targeting both epidermal growth factor receptor (EGFR/ErbB1) and human epidermal growth factor receptor 2 (HER2/ErbB2).
Oxaliplatin

Oxaliplatin

Oxaliplatin (CAS 61825-94-3), chemically designated as cis-[(1R,2R)-1,2-cyclohexanediamine-N,N′][oxalato(2-)-O,O′]platinum(II), is a third-generation platinum-based antineoplastic agent. The molecule features a central platinum(II) ion coordinated by a bidentate oxalate leaving group and a bulky (1R,2R)-cyclohexanediamine (DACH) carrier ligand.
Carboplatin

Carboplatin

Carboplatin (CAS 41575-94-4), chemically designated as cis-diammine(cyclobutane-1,1-dicarboxylato)platinum(II), is a second-generation platinum-based antineoplastic agent developed to improve upon cisplatin's clinical profile .
X
We use cookies to offer you a better browsing experience, analyze site traffic and personalize content. By using this site, you agree to our use of cookies. Privacy Policy
RejectAccept